Erschienen in:
11.09.2020 | Original Article
Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma
verfasst von:
Hualong Zheng, YaJun Zhao, Qingliang He, Hankun Hao, Yantao Tian, Bingbing Zou, Lixin Jiang, Xiantu Qiu, Yanbing Zhou, Zhi Li, Yanchang Xu, Gang Zhao, Fangqin Xue, Shuliang Li, Weihua Fu, Yongxiang Li, Xiaojun Zhou, Yong Li, Zhenggang Zhu, Jinping Chen, Zekuan Xu, Lisheng Cai, En Li, Honglang Li, Jianwei Xie, Chaohui Zheng, Jun Lu, Ping Li, Changming Huang
Erschienen in:
Gastric Cancer
|
Ausgabe 2/2021
Einloggen, um Zugang zu erhalten
Abstract
Objective
To establish a novel nomogram to predict individual 1, 3, and 5 years disease-free survival (DFS) of patients with gastric neuroendocrine carcinoma/mixed adenoneuroendocrine carcinoma [(MA)NEC].
Background
Among patients undergoing radical resection of gastric (MA)NEC, there is still a high tendency for relapse.
Methods
A retrospective analysis of 777 patients with gastric (MA)NEC at 23 centers in China from 2004 to 2015 was performed. Based on the established nomogram, which included age, ASA, pT, pN and Ki67, the overall patients were divided into low-risk group (LRG) and high-risk group (HRG).
Results
The median follow-up time was 40 months (1–169 months). The C-index, AUC and time-ROC of the nomogram were significantly higher than that of the 8th edition AJCC and ENETS TNM staging systems. The 3-year DFS of patients in HRG generated by the nomogram was significantly lower than that in LRG (all patients: 35% vs 66.9%, p < 0.001), and there were still significant differences in stratified analysis of the TNM staging systems. The local recurrence rate (10.5% vs 2.6%) and distant recurrence rate (45.1% vs 22.6%) in HRG were significantly higher than those in LRG, especially in anastomotic recurrence (6.3% vs 2%), liver recurrence (20.7% vs 13.4%) and peritoneal metastasis (12.7% vs 2.6%).
Conclusions
Compared with AJCC and ENETS TNM staging systems, the established novel validated nomogram had a significantly better prediction ability for DFS and recurrence patterns in patients with gastric (MA)NEC. It can also compensate for the shortcomings of existing AJCC and ENETS TNM staging in predicting individual recurrence risk.